BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy

作者：Lele Zhang, Zhen Gao, Hong Pan, Ruonan Li, Liwei Fang, Weiwang Li, Jingyu Zhao, Xiaohong Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Yuechen Luo, Jun Shi · 发表于：New England Journal of Medicine · 年份：2025 · DOI：10.1056/nejmc2502297 · 被引用次数：26 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、Blood groups and transfusion

Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement.